欢迎访问ProbeChem中文网站，英文网站请访问www.probechem.com
    英文 |     中文

产品咨询: sales@probechem.com
订购: order@probechem.com

首页-小分子抑制剂&激动剂-Epigenetics-Histone Methyltransferase (HMTase)-SCR-6920
SCR-6920

Chemical Structure : SCR-6920

CAS No.: 2756849-68-8

加入收藏

SCR-6920 (SCR6920)

货号: PC-26595Not For Human Use, Lab Use Only.

SCR-6920 is a potent and selective, oral PRMT5 inhibitor with IC50 of 1.48 nM.

规格 价格 库存 数量
50 mg Get quote
100 mg Get quote
250 mg Get quote
获取报价单
* 请选择数量再加入购物车
 or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

纯度 & COA & 质检文件 纯度: >98% (HPLC)

生物&药学活性

SCR-6920 is a potent and selective, oral PRMT5 inhibitor with IC50 of 1.48 nM.
SCR-6920 binds to substrate pocket, adjacent to the binding site of the cofactor SAM, does not affect the binding of MEP50 to PRMT5.
SCR-6920 shows no inhibitory activity against other TRPM family members such as PRMT1, PRMT3, PRMT6, and PRMT8 (IC50>50 uM).
SCR-6920 demonstrates broad antitumor activities on a range of tumors with IC50 of <600 nM for 15 out of 25 for lung cancer, 5 out of 6 for ovarian cancer, 9 out of 14 for breast cancer, 3 out of 3 for head and neck cancer, 3 out of 4 for bladder cancer, and 4 out of 4 for lymphoma.
SCR-6920 has IC50 values of 17.5 nmol/L (A375), 7.4 nmol/L (A549), 10.4 nmol/L (MDA-MB-468), 8.4 nmol/L (5637), 3.42 nmol/L (Z138), and 15.6 nmol/L (Raji), with minimal cytotoxicity to nonmalignant cell lines.
SCR-6920 regulates transcription profiles associated with DNA damage and angiogenesis in ovarian cancer.
SCR-6920 downregulates hypoxia-inducible factor-1α (HIF-1α) through the ubiquitin–proteasome degradation pathway, thereby reducing downstream VEGF expression and secretion.
SCR-6920 demonstrates a synergistic effect for SCR-6920 combined with bevacizumab against ovarian cancer.

物理化学性质&存储条件

分子量 546.71
分子式 C32H42N4O4
外观性状 Solid
CAS No.
储存条件
固体粉末
-20°C 12 个月; 4°C 6 个月
配置液
-80°C 6 个月; -20°C 6 个月
Shipping
Solubility

10 mM in DMSO
Chemical Name/SMILES

1-ethyl-4-((R)-2-hydroxy-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)ethyl)-8-(2-methoxy-7-azaspiro[3.5]nonane-7-carbonyl)-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-one

参考文献

1. Yang G, et al. Mol Cancer Ther. 2026 Apr 21. doi: 10.1158/1535-7163.MCT-25-1105.

备案号：沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

联系我们 sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

询单

  • *产品名称:
  • *姓名:
  • *邮箱:
  • *公司名称:
  • *询单数量:
  • *国籍:
  • 询单信息: